Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1626 1673 1693
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18563804 | MACROLIDE COMPOUNDS | Non-Final OA | VANDERBILT UNIVERSITY |
| 18562025 | Process for Purifying Nucleic Acids, in particular in a Microfluidic Apparatus | Non-Final OA | Robert Bosch GmbH |
| 17908069 | Method for Treating a Biological Sample, and Device for Isolating Cells from a Transport Medium | Non-Final OA | Robert Bosch GmbH |
| 18281202 | NOVEL COMPOUND OR SALT THEREOF, AND ANTITUMOR ACTIVATOR CONTAINING SAME AS ACTIVE INGREDIENT | Non-Final OA | TOHOKU UNIVERSITY |
| 17753103 | COMPOSITION COMPRISING AMPS POLYMER AND POLYSACCHARIDE | Final Rejection | L'OREAL |
| 18796218 | USE OF IGF-2 RECEPTOR AGONIST LIGANDS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM | Non-Final OA | New York University |
| 18378404 | OMEGA-3 FATTY ACID AND VITAMIN D LEVELS TO IDENTIFY AND ATTENUATE COGNITIVE AGING IN INDIVIDUALS | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 16980064 | BETA GLUCAN AND CD40 AGONIST COMBINATION IMMUNOTHERAPY | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18334456 | LIQUID COMPOSITION COMPRISING HYDROXYPROPYL METHYL CELLULOSE AND ORGANIC SOLVENT | Non-Final OA | Shin-Etsu Chemical Co., Ltd. |
| 17799546 | SMALL MOLECULES FOR TREATING AGE-RELATED RETINAL DISEASES | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17996117 | COMPOSITION CONTAINING NUCLEIC ACID OLIGOMER | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18779835 | NUCLEIC ACID PREPARATION COMPOSITIONS AND METHODS | Non-Final OA | SEQUENOM, INC. |
| 17864828 | Delivery of Active Agents | Non-Final OA | MannKind Corporation |
| 18548711 | PURIFICATION METHODS FOR OLIGOMERIC COMPOUNDS | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18284614 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | Non-Final OA | Sinai Health System |
| 18084954 | METHODS OF MAINTAINING OR INCREASING GROWTH OR COGNITIVE DEVELOPMENT | Non-Final OA | Fonterra Co-Operative Group Limited |
| 18563005 | PROCESS FOR THE MANUFACTURE OF CARBOXYLIC ANHYDRIDE | Non-Final OA | Cerdia International GmbH |
| 18561644 | METHODS OF TREATING MEDICAL CONDITIONS AND INHIBITING LINE1 REVERSE TRANSCRIPTASE USING A SUBSTITUTED 4-FLUORO-2,5-DIHYDROFURANYL PHOSPHONIC ACID OR RELATED COMPOUND | Non-Final OA | ROME Therapeutics, Inc. |
| 18560536 | ORAL SOLUTION BASED ON CITICOLINE AND NICOTINAMIDE FOR USE IN THE TREATMENT OF GLAUCOMA | Non-Final OA | Omikron Italia S.r.l. |
| 16907592 | PHENOL-FREE ACID-FAST BACTERIA SOLUTION | Non-Final OA | Ventana Medical Systems, Inc. |
| 18495033 | DISSOLUTION OF CHITOSAN IN APROTIC AQUEOUS MEDIUM COMPOSITION, PREPARATION METHODS AND BIOMEDICAL USES THEREOF | Non-Final OA | Oligo Médic inc |
| 18379685 | METHODS AND COMPOSITIONS FOR TREATING LONG COVID-19 | Non-Final OA | Intrinsic Medicine, Inc. |
| 18553615 | NONENYL SUCCINIC ANHYDRIDE MODIFIED STARCH, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | Guantian LI |
| 18553278 | INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE (NNMT) | Non-Final OA | UNIVERSITEIT LEIDEN |
| 17289221 | FLAVIN ADENINE DINUCLEOTIDE (FAD) FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Non-Final OA | BIO EVEN |
| 18547001 | Compounds Useful in HIV Treatment | Non-Final OA | ViiV Healthcare Company |
| 18546609 | PROCESS FOR PREPARING AN E-SELECTIN INHIBITOR INTERMEDIATE | Non-Final OA | GLYCOMIMETICS, INC. |
| 17785251 | METHOD FOR ENRICHING VESICULAR RNA | Non-Final OA | QIAGEN GmbH |
| 17757453 | INJECTABLE MIXTURES OF HYALURONIC ACID FOR USE IN DERMO-AESTHETICS | Non-Final OA | Altergon S.A. |
| 17289611 | METHOD OF EXTRACTING MIRNA AND METHOD OF ANALYZING MIRNA | Non-Final OA | CRAIF INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy